

Published September 2021

Hormone Replacement Therapy (HRT)

# Benefits and Risks – The Facts

### The Menopause

Women make up 51% of the population, however the menopause and the impact of this natural change on women is often seen as a taboo subject.

The average age of the menopause is 51, although this age can vary greatly. The menopause itself only lasts for one day, because it simply marks the one-year anniversary since your last period. Perimenopause is perhaps a more accurate term to describe the period of time in which you will have cycles but start to experience “menopausal” symptoms.

This period of hormonal change can last from between 2 – 12 years. For many women they can pass through the perimenopause without any significant issues, while for others they may experience a range of challenges and issues.

For some women they want to manage this change “naturally” while others would prefer a medical intervention such as hormone replacement therapy. There is no right or wrong, when it comes to managing the menopause and the options available to us often come down to individual circumstances and preferences.

This booklet to outlines one option that can be used by women to help manage the change - Hormone Replacement Therapy (HRT) and to provide you with an unbiased outline of the benefits and risks, should you consider this approach to managing the menopause.

**The British Menopause Society** – [www.thebms.org.uk](http://www.thebms.org.uk)

**NHS Information** – www.patient.co.uk/menopause

### Hormone Replacement Therapy (HRT) introduction

Hormone Replacement Therapy or more commonly referred to as HRT is a prescription only treatment that replaces some of the lost oestrogen and progestogen hormones which occur during menopause. It can be used to relieve symptoms of menopause. If an early menopause has occurred, it is often recommended that a woman takes HRT until she reaches the usual menopause age – in particular to maintain bone and heart health.

In recent years there have been concerns raised about HRT and the potential risks to various aspects of women’s health.

This leaflet sets out the known facts about HRT. If briefly summarises the results of studies regarding its safety and addresses the controversy that still surrounds its use.

### HRT Misinformation

In the 1990’s two of the largest studies on HRT were undertaken; a clinical randomised trial in the USA Women’s Health Initiative (WHI), and an observational questionnaire in the UK – Million Women Study (WMS). The initial results of these two studies were published during 2002 and 2003 and raised concerns regarding the safety of HRT. In particular, results suggested that prolonged use of HRT increases the risk of breast cancer, and that HRT can increase the risk of heart disease.

The findings received wide publicity and caused panic amongst users and healthcare professionals. As a result many women chose to, or were advised to, stop taking their HRT.

A number of expert panels, including The British Menopause Society, responded by indentifying flaws and shortcomings with both studies:

*The women in the WHI study were North American. Many were obese and in their mid-sixties. Their risk of cancer, stroke and heart disease would therefore be higher than in younger, non-obese women. WHI only looked at one dose and type of HRT. The dose used was considered too high (by UK experts) for these older women and would generally not be used in the UK. Therefore the results are not comparable to common practice in the UK.*

MWS’s research methodology has been criticised. The women were self-selecting and self-reporting HRT users, many dropped out of the study, and since it was not a randomised controlled trial, there wasn’t a control group to compare findings against. Follow up was undertaken through cancer registries, not by further questionnaires – so changes in HRT usage after initial registration were not recorded.

When the full WHI results were subsequently published it showed that the apparent increased risk of breast cancer was only found in women who were already taking HRT before entering the study.

The authors of WHI now state that the risk of breast cancer was exaggerated:

*Increase in risk of breast cancer with combined HRT in WHI was much less than initially reported and equates to 4 extra cases per 1000 women after 5 years use (this risk is less than that caused by smoking 10 cigarettes/day, alcohol and obesity). Other risks were exaggerated whilst benefits for middle-aged women were disregarded.*

In addition, whereas the reports initially claimed that there was no difference in risks with age, further analysis of the WHI report confirms that starting HRT after the age of 60 may increase the risks of heart disease. Both studies showed no increase in heart disease in women starting HRT within 10 years of the menopause.

Follow up studies carried out by some of WHI’s leading investigators now say that the benefits of HRT outweigh the risk for healthy women in their 50’s who are suffering from menopause symptoms. Dr Robert Langer, Principal Investigator of WHI says “with 10 years hindsight we can put the lessons learned from the WHI trial into perspective.   
Over generalising the results from the women who were, on average, 12 years post menopause to all (younger) post menopause women has led to needless suffering and lost opportunities for many. A further report from Dr Langer, published 2017, concludes that:

“*it is time to get past the misinformation and hysteria generated by the highly irregular circumstances of the WHI and stop denying potential benefits (control of vasomotor symptoms, prevention of fractures and coronary heart disease) to women*.”

### HRT benefits and risk

Level of risk for HRT use has actually remained unchanged for many years. In 2015, NICE published the first national Menopause guidance. A review of risks and benefits of UK prescribed HRT was undertaken. Their findings are in line with the full published results of both WHI and MWS.

The findings are summarised in the tables below with the overarching conclusion that generally, for health, younger women, within 10 years of their menopause, the benefits   
of HRT outweigh the risk. However, older women, over 60 years of age and beyond, are often at higher risk of cardiovascular disease, and therefore, the risk of HRT often outweighs the benefits.

**Table 1:** Absolute rate of coronary heart disease for different type of HRT compared with no HRT (or placebo), different durations of HRT use and time since stopping HRT for menopausal women.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | | Difference in coronary heart disease incidence per 1000 menopausal women over 7.5 years (95% confidence interval) (baseline population risk in the UK over 7.5 years: 26.3 per 1000₁ | | | |
| Current HRT  users | Treatment duration  <5 years | Treatment duration  5-10 years | >5 years since stopping  treatment |
| Women on oestrogen alone | RCT estimate² | 6 fewer  (-10 to 1) | No available  data | No available  data | 6 fewer  (-9 to -2) |
| Observational  Estimate³ | 6 fewer  (-9 to -3) | No available  data | No available  data | No available  data |
| Women on oestrogen & progestogen | RCT estimate² | 5 more  (-3 to 18) | No available  data | No available  data | 4 more  (-1 to 11) |
| Observational  Estimate³ | No available  data | No available  data | No available  data | No available  data |
| HRT (Hormone Replacement Therapy; RCT (Randomised Controlled Trial)  For full source references, see Appendix M in the full guideline  ¹ Results from Weiner 2008 were used for the baseline population risk estimation  ² For women aged 50-59 years at entry to the RCT.  ³ Observational estimates are based on cohort studies with several thousand women | | | | | |

**Table 2:** Absolute rates of stroke for different types of HRT compared with no HRT   
(or placebo), different durations of HRT use and time since stopping HRT for   
menopausal women.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | | Difference in Stroke incidence per 1000 menopausal women over 7.5 years (95% confidence interval) (baseline population risk in the UK over 7.5 years: 26.3 per 1000₁ | | | |
| Current HRT  users | Treatment duration  <5 years | Treatment duration  5-10 years | >5 years since stopping  treatment |
| Women on oestrogen alone | RCT estimate² | 0  (-5 to 10) | No available  data | No available  data | 1 more  (-4 to 9) |
| Observational  Estimate³ | 3 more  (-1 to 8) | No available  data | No available  data | No available  data |
| Women on oestrogen & progestogen | RCT estimate² | 6 more  (-2 to 21) | No available  data | No available  data | 4 more  (-1 to 13) |
| Observational  Estimate³ | 6 more  (-2 to 21) | No available  data | No available  data | No available  data |
| HRT (Hormone Replacement Therapy; RCT (Randomised Controlled Trial)  For full source references, see Appendix M in the full guideline  ¹ Results from Weiner 2008 were used for the baseline population risk estimation  ² For women aged 50-59 years at entry to the RCT.  ³ Observational estimates are based on cohort studies with several thousand women | | | | | |

In conclusion, for the majority of women, HRT is a safe and appropriate option – in conjunction with improving lifestyle. It is generally recommended that the lowest dose of hormone to relieve symptoms is prescribed. Although it is an individual decision when to stop HRT, risks will increase with age – particularly after 60 years of age.

### Benefits of HRT

The most noticeable effects of taking HRT are a reduction in menopausal symptoms, which can often respond quite rapidly to treatment.

Perhaps even more importantly, HRT provides significant protection against osteoporosis; however, HRT is only licensed for second-line use in the prevention of osteoporosis. Although it is recommended that HRT offers some protections against cardiovascular disease and dementia, it is also not licensed for these purposes.

There are many different types of HRT preparations and doses available, so it is possible that not every woman will find that the first HRT she tries is the one that suits her best. It is recommended that at least 3 months commitment to a dose and preparation of HRT is necessary to fully assess its effectiveness.

If you do decide to use HRT then it is recommended that all women using HRT have a yearly check-up with their GP

### The different forms of HRT

#### Main Classes of HRT

There are three major types of HRT, and the one a woman receives will depend on whether she has just begun her menopause and is postmenopausal, or whether she has had a natural or surgical menopause.

1. **Oestrogen Only HRT:**

This is recommended for women who have had their womb removed by a hysterectomy. Because the role of progestogen is to protect the womb lining (endometrium), this group of women generally do not need progestogen and are therefore usually prescribed oestrogen only HRT (See hysterectomy and   
menopause leaflet).

1. **Cyclical or Sequential HRT:**

This HRT is recommended for women who have had a natural menopause, or who are approaching the menopause, but are still having periods (perimenopause). Cyclical HRT contains oestrogen and a progestogen (a form of progesterone) and this will produce regular bleeding to protect the endometrium.

1. **Continuous Combined or Period-Free HRT:**

This is recommended for women who have not had a periods for a least one year and are therefore post-menopausal. Period-free HRT contains similar hormones to cyclical HRT but, does not stimulate period bleeding. Period-free HRT can be started straight away if you have not previously been on any HRT and are post-menopausal. Swapping from cyclical HRT to period-free HRT is recommended after 5 years of cyclical HRT usage, or at age 54.

#### Tablets, Patches & Gels

HRT is most commonly prescribed in tablet form and there are many different brands available containing varying combinations of oestrogen alone or in combination with progestogen. HRT can also be prescribed in patch or gel transdermal forms. Also “local “HRT includes creams, vaginal tablets pessaries and rings which are inserted in to the vagina, where the oestrogen helps reduce vaginal dryness.

Transdermal preparations are particularly useful for women with bowel dysfunction (IBS, Crohn’s, Diverticulitis etc), or a history of clotting problems. Previously hormones could be delivered via implants that lasted approximately 6 months at a time. Unfortunately, implants are currently not being manufactured or available on the NHS in the UK.

#### Side Effects to HRT

Side-effects with HRT are uncommon. In the first few weeks some women may develop slight nausea, some breast discomfort or leg cramps. These tend to settle within a few weeks. Some women report more headaches or migraines while taking HRT. Skin irritation can occur rarely with HRT patches.

#### Contraindications to Taking HRT

HRT may not be recommended for some women with –

* A history of gynaecology cancers
* A history of blood clots (DVT, PE, stroke)
* A history of heart attack
* Uncontrolled hypertension
* Severe liver disease
* Pregnancy
* Undiagnosed vaginal bleeding
* Undiagnosed breast lump

### Contraception and the change

HRT does not generally have a contraceptive effect (exceptions include Mirena IUS ). Therefore you should continue to use an alternative, non-hormonal form of contraception for one year after last period if over 50 years of age,   
and two years if less than 50

### Making a change

Simple lifestyle changes (for example – reducing alcohol and caffeine, reducing/stopping smoking, losing excess weight and increasing exercise) will also definitely improve menopause symptoms, and reduce risk of age-related diseases.

Non-hormonal alternatives to HRT are also available and for more information on this and the menopause:

### Further reading and useful references:

British Menopause Society www.thebms.org.uk

Menopause Matters www.menopausematters.co.uk

National Institute for Health and Care www.nice.org.uk/guidance/nh23

Excellence (NICE) 2015 Menopause

NHS Patient Information www.patient.co.uk/menopause

Royal College of Obstetricians and www.rcog.org.uk/en/patients

Gynaecologists (RCOG) Menopause